CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Undecimal Bio launches with $18M to take siRNA beyond liver disease

Positive
AI Analysis

Summary

Undecimal Bio launched with $18 million in funding after spinning out from Eleven Therapeutics, aiming to expand siRNA therapeutic applications beyond liver disease, competing in the space with companies like Alnylam and Arrowhead.

Importance:5/10
Sentiment:
0.60
spinoutsiRNAfundingliver disease
Related Companies

Read the original article

Published by Endpoints News on October 12, 2026 11:00 AM

Read Original